The Renton, Wash.-based system’s decision mirrors those recently made by Cleveland Clinic and New York City-based Mount Sinai.
Providence decided not to administer Aduhelm at this time because of the ongoing investigation of the drug’s approval, as well as its risks and the lack of clear evidence demonstrating clinical benefit, a spokesperson told Becker’s July 16.
“We understand that people living with Alzheimer’s and their families are seeking disease-modifying treatments, and we are hopeful that with more research, we will soon be able to offer such a treatment to improve the lives of our patients and families,” Providence said.
Providence said it will reevaluate Aduhelm’s potential use for its patients when the investigation is complete and more data on the drug’s clinical benefit becomes available.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
